Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

@article{Murray2002Interleukin10I,
  title={Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.},
  author={Henry W. Murray and Christina M Lu and Smita Mauze and Sherry Freeman and Andr{\'e} L. C. Moreira and Gilla Kaplan and Robert Lee Coffman},
  journal={Infection and immunity},
  year={2002},
  volume={70 11},
  pages={6284-93}
}
Interleukin-10 (IL-10) is thought to promote intracellular infection, including human visceral leishmaniasis, by disabling Th1 cell-type responses and/or deactivating parasitized tissue macrophages. To develop a rationale for IL-10 inhibition as treatment in visceral infection, Th1 cytokine-driven responses were characterized in Leishmania donovani-infected BALB/c mice in which IL-10 was absent or overexpressed or its receptor (IL-10R) was blockaded. IL-10 knockout and normal mice treated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 114 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 61 references

Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines.

Transactions of the Royal Society of Tropical Medicine and Hygiene • 2001
View 14 Excerpts
Highly Influenced

Clinical and experimental advances in treatment of visceral leishmaniasis.

Antimicrobial agents and chemotherapy • 2001
View 14 Excerpts

Similar Papers

Loading similar papers…